Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

GRAVITAS-309: A Phase 2/3 Study of Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

NCT03584516 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT03584516
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03584516 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
GRAVITAS-309: A Phase 2/3 Study of Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
Lead sponsor
Incyte Corporation
Phase
Phase 2/3
Overall status
Terminated
Start date
January 17, 2019
Completion date
November 3, 2023
Enrollment
155 (actual)
Sites
133

Conditions

As the registry lists them; a condition with its own page is linked.

chronic graft-versus-host disease